13 reports of this reaction
3.5% of all OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, manufactured by Accord Healthcare Inc.. There are 13 FDA adverse event reports linking OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE to FATIGUE. This represents approximately 3.5% of all 373 adverse event reports for this drug.
Patients taking OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 13 FDA reports for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.5% of all adverse event reports for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, making it one of the most commonly reported side effect.
If you experience fatigue while taking OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.